TABLE 2.
Fatty liver index and Fibrosis‐4 score (% of cases in different cells) at baseline and after 6 and 12 mo of treatment by the different drug classes
| CTRL group (n = 165) | DPP‐4I group (n = 104) | GLP‐1RA group (n = 338) | SGLT‐2I group (n = 195) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6‐mo | 12‐mo | Baseline | 6‐mo | 12‐mo | Baseline | 6‐mo | 12‐mo | Baseline | 6‐mo | 12‐mo | |
| Fatty liver index (%) | ||||||||||||
| No steatosis (<30%) | 0.6 | 0.6 | 0.6 | 5.8 | 5.8 | 9.6 | 0.0 | 0.9 | 0.6 | 3.6 | 5.6 | 7.2 |
| Undetermined (30%‐60%) | 9.7 | 11.5 | 9.7 | 25.8 | 27.9 | 24.0 | 3.0 | 3.8 | 6.8 | 8.2 | 14.9 | 15.9 |
| Steatosis (>60%) | 89.7 | 87.9 | 89.7 | 68.4 | 66.3 | 66.4 | 97.0 | 95.3 | 92.6 | 88.2 | 79.5 | 76.9 |
| P vs baseline a | NS | NS | NS | NS | NS | 0.004 | 0.027 | 0.005 | ||||
| Fibrosis‐4 score | ||||||||||||
| No advanced fibrosis (<1.30) | 39.4 | 44.2 | 43.6 | 50.0 | 49.0 | 52.9 | 52.9 | 67.2 | 73.1 | 51.3 | 65.6 | 70.8 |
| Undetermined (1.30‐2.67) | 57.0 | 53.3 | 52.8 | 45.2 | 47.1 | 45.2 | 44.4 | 30.5 | 25.7 | 45.1 | 30.8 | 27.2 |
| Advanced fibrosis (>2.67) | 3.6 | 2.5 | 3.6 | 4.8 | 3.9 | 4.8 | 2.7 | 2.4 | 1.2 | 3.6 | 3.6 | 2.1 |
| P vs baseline b | 0.045 | NS | NS | NS | <0.001 | <0.001 | 0.004 | <0.001 | ||||
Abbreviations: CTRL, controls; DPP‐4Is, dipeptidyl‐peptidase‐4 inhibitors; GLP‐1RAs, glucagon‐like peptide‐1 receptor agonists; NS, not significant; SGLT‐2Is, sodium‐glucose cotransporter‐2 inhibitors.
a
Calculated on percent of cases positive for steatosis.
b
Calculated on percent of cases defined as “no advanced fibrosis”.